- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMX Aktie jetzt für 0€ handeln | |||||
| Di | BiomX stock holds Buy rating at H.C. Wainwright as Phase 2b trial begins | 2 | Investing.com | ||
| Di | BiomX stock maintains Buy rating at H.C. Wainwright with $15 price target | 1 | Investing.com | ||
| Mo | BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy | 2 | Investing.com | ||
| Mo | BiomX-Aktie schießt nach Start von Phase-2b-Studie für Mukoviszidose-Therapie in die Höhe | 3 | Investing.com Deutsch | ||
| Mo | BiomX startet Phase-2b-Studie mit Phagentherapie gegen Infektionen bei Mukoviszidose | 1 | Investing.com Deutsch | ||
| Mo | BiomX begins phase 2b trial for phage therapy targeting CF infections | 1 | Investing.com | ||
| Mo | BiomX Inc: BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis | 154 | GlobeNewswire (Europe) | First patient dosing in Company's Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections in Cystic Fibrosis patients; topline results... ► Artikel lesen | |
| 08.07. | BiomX Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.06. | BiomX Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 16.05. | H.C. Wainwright cuts BiomX stock target to $15, maintains Buy | 6 | Investing.com | ||
| 15.05. | BiomX Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | BiomX Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 15.05. | BiomX GAAP EPS of -$0.33 beats by $0.03 | 7 | Seeking Alpha | ||
| 15.05. | BiomX Inc. Bottom Line Retreats In Q1, But Beats Estimates | 1 | RTTNews | ||
| 15.05. | BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates | 101 | GlobeNewswire (Europe) | In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on... ► Artikel lesen | |
| 14.05. | A Look at BiomX's Upcoming Earnings Report | 6 | Benzinga.com | ||
| 23.04. | BiomX Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.04. | BiomX Inc. - S-1, General form for registration of securities | 3 | SEC Filings | ||
| 04.04. | H.C. Wainwright maintains BiomX stock Buy rating, $21 target | 12 | Investing.com | ||
| 01.04. | BiomX stock target soars to $21 on Phase 2 trial success | 2 | Investing.com |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 94,40 | -2,13 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
| AMGEN | 253,90 | +0,10 % | Amgen: Robustes Pharma-Geschäft und Dividende | Die Amgen-Aktie stellt eine attraktive Depotbeimischung für jedes diversifizierte oder Pharma-orientierte Anlegerdepot dar. Die Bewertung ist vergleichsweise günstig, die Aussichten stabil. Und es gibt... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,230 | +1,65 % | INOVIO Pharma Announces Proposed Public Offering | WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof)... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,988 | -3,14 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,189 | +1,21 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,930 | -20,25 % | RedHill Biopharma Ltd.: RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer | Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and... ► Artikel lesen | |
| FIBROGEN | 7,930 | -2,22 % | FibroGen lockert Finanzierungsbedingungen und senkt Mindestliquiditätsanforderung | ||
| LEXAGENE | - | - | LexaGene Holdings Inc. - REVOKED, Commission order revoking Exchange Act registration [Section 12(j)] | ||
| ALLAKOS | 0,255 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 15.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 15.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 15.05.2025.ISIN NameCA05259R1073 AUSTRALIS... ► Artikel lesen | |
| VAXCYTE | 32,200 | +3,21 % | Vaxcyte, Inc.: Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | -- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 0,713 | +2,15 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer | WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases... ► Artikel lesen | |
| HOOKIPA PHARMA | 1,150 | 0,00 % | HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock | NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, "HOOKIPA"), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 2,560 | -1,16 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| QIAGEN | 41,405 | -0,35 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| NUVALENT | 83,40 | -2,67 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen |
BIOMX INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,380 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.